Albert Farrugia (A Farrugia)

Loop profile Scopus Author ID Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 24

Top Topics

Quality Control

Cardiac Surgery

Placebo Controlled

Top Venues

Haemophilia : the official journal of the World Federation of Hemophilia

Pathogens (Basel, Switzerland)

This page only lists publications with an associated author ORCID identifier.

Publications

Martine Pergent, Johan Prevot, Leire Solis, Albert Farrugia
Immunoglobulin solutions for patients with primary immunodeficiency. Comments on Burnouf et al.'s 'Stepwise options for preparing therapeutic plasma proteins from domestic plasma in low- and middle-income countries'. Vox sanguinis (2024)
Albert Farrugia, Robert Perry, Françoise Rossi, Leni von Bonsdorff, Glynis Bowie, Jean-Claude Faber, Jeh-Han Omarjee, Jay Epstein, Jenny White
Generating pathways to domestically sourced plasma-derived medicinal products: Report from a workshop by the International Plasma and Fractionation Association and the Working Party on Global Blood Safety of the International Society of Blood Transfusion. Vox sanguinis (2024)
Albert Farrugia
A Sociology of Plasma Proteins - A Technocrat's Perspective. International journal of social determinants of health and health services (2024)
Albert Farrugia
Use of automated haematology analysers for the quality control of blood components for transfusion: Comment on Valina et al. (Transfusion Medicine 2024;34:30-38). Transfusion medicine (Oxford, England) (2024)
Albert Farrugia
Use of automated haematology analysers for the quality control of blood components for transfusion: Comment on Valina et al. (Transfusion Medicine 2024;34:30-38). Transfusion medicine (Oxford, England) 34 (3) (2024)
Albert Farrugia
The Evolution of the Safety of Plasma Products from Pathogen Transmission-A Continuing Narrative. Pathogens (Basel, Switzerland) 12 (2) (2023)
Albert Farrugia
The Evolution of the Safety of Plasma Products from Pathogen Transmission-A Continuing Narrative. Pathogens (Basel, Switzerland) 12 (2) (2023)
Albert Farrugia
The Evolution of the Safety of Plasma Products from Pathogen Transmission-A Continuing Narrative. Pathogens (Basel, Switzerland) 12 (2) (2023)
Albert Farrugia
In response: Overestimation of fibrinogen concentration in cryoprecipitate by repeated freeze-thawing with long thawing period as used in the Clauss method. Transfusion 63 (10) (2023)
Albert Farrugia
The Evolution of the Safety of Plasma Products from Pathogen Transmission-A Continuing Narrative. Pathogens (Basel, Switzerland) 12 (2) (2023)
Albert Farrugia
The World Health Organisation's list of essential medicines and haemophilia treatment products. Haemophilia : the official journal of the World Federation of Hemophilia (2023)
Albert Farrugia, Cees Smit, Andrea Buzzi
The legacy of haemophilia: Memories and reflections from three survivors. Haemophilia : the official journal of the World Federation of Hemophilia 28 (5) (2022)
Albert Farrugia
Fresh frozen plasma: Beyond coagulation factor content. Transfusion medicine (Oxford, England) 32 (2) (2022)
Albert Farrugia
Storage of cryoprecipitate: Role of blood storage. Transfusion 61 (9) (2021)
Albert Farrugia, Cees Th Smit Sibinga
The discovery of cryoprecipitate as a modality for hemophilia A: Augmenting the allocation of credit. Transfusion 61 (8) (2021)
Albert Farrugia
Appropriately specifying the quality of plasma for fractionation. Vox sanguinis (2021)
Albert Farrugia, Megha Bansal, Ivan Marjanovic
Estimation of the latent therapeutic demand for immunoglobulin therapies in autoimmune neuropathies in the United States. Vox sanguinis (2021)
Albert Farrugia, Jim MacPherson, Michael P Busch
Convalescent plasma - this is no time for competition. Transfusion 60 (7) (2020)
Giancarlo Castaman, Alessandra Borchiellini, Elena Santagostino, Giuseppe Tagariello, Margit Serban, Marusia Uscatescu, Cristina Truica, Albert Farrugia, Massimo Morfini
Pharmacokinetics of a new human plasma-derived double virus inactivated and nanofiltered factor IX concentrate in previously treated severe or moderately severe haemophilia B patients. Haemophilia : the official journal of the World Federation of Hemophilia 25 (6) (2019)
Albert Farrugia, Giancarlo Liumbruno, Gabriele Calizzani, Fabio Candura, Samantha Profili, Josephine Cassar
Improving access to haemophilia therapies-Beyond humanitarian aid. Haemophilia : the official journal of the World Federation of Hemophilia 24 (6) (2018)
Albert Farrugia, A Gringeri, Sylvia von Mackensen
The multiple benefits of sport in haemophilia. Haemophilia : the official journal of the World Federation of Hemophilia 24 (3) (2018)
V G Guedes, Sylvia Thomas, Albert Farrugia, P A Wachholz, S A L Souza
Perspectives on haemophilia access in Brazil? Haemophilia : the official journal of the World Federation of Hemophilia 24 (4) (2018)
Albert Farrugia
Time to review the way we estimate access to haemophilia concentrates worldwide. Haemophilia : the official journal of the World Federation of Hemophilia 23 (3) (2018)
Albert Farrugia, U Schlenkrich
Concerns regarding clinical trials in haemophilia-Augmenting Iorio's "Research and policy implications of a recently published controlled study in previously untreated haemophilia patients at high risk of inhibitor development" Haemophilia (2017), 1-3 https://doi.org/10.1111/hae.13176. Haemophilia : the official journal of the World Federation of Hemophilia 23 (5) (2017)